{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-016182","form_type":"8-K","ticker":"BPTH","cik":"0001133818","company_name":"BIO-PATH HOLDINGS, INC.","filed_at":"2024-12-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.758290+00:00","generated_at":"2026-05-29T03:51:51.901111+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bio-Path outlines obesity program for BP1001-A; discontinues BP1002 Phase 1 trial","bullets":["BP1001-A aims to treat obesity in Type 2 diabetes by downregulating Grb2 to enhance insulin signaling.","IND-enabling testing for BP1001-A expected in Q4 2024; preclinical studies ongoing.","Discontinues Phase 1 study of BP1002 for lymphoma/CLL due to enrollment challenges.","Company reallocates resources to metabolic program from oncology pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-016182","json":"https://secwatch.observer/filing/0001558370-24-016182.json","markdown":"https://secwatch.observer/filing/0001558370-24-016182.md","text":"https://secwatch.observer/filing/0001558370-24-016182.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133818/000155837024016182/0001558370-24-016182-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133818/000155837024016182/bpth-20241211x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T03:51:51.901111+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}